Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183116 | 0.84 | ALDH1A1 (0.43) | EPHX1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10903240 | 0.80 | NOS2 (0.40) | EPHX1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9737609 | 0.79 | NOS2 (0.43) | — | |
| SCHEMBL146828 | 0.78 | NOS2 (0.46) | — | |
| SCHEMBL995604 | 0.78 | NOS2 (0.46) | — | |
| SCHEMBL6859669 | 0.78 | NOS2 (0.46) | — | |
| SCHEMBL23458246 | 0.78 | NOS2 (0.41) | CYP3A4 | |
| SCHEMBL17676973 | 0.78 | EPHX1 (0.48) | EPHX1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5157107 | 0.78 | EPHX1 (0.48) | EPHX1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7265700 | 0.78 | EPHX1 (0.48) | EPHX1RAB9ANPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186098-A1 | Method for preventing and treating hearing loss using sensorineurotrophic compounds | AMGEN INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020042442-A1 | Ureas and carbamates of N-Heterocyclic carboxylic acids and carboxylic acid isosteres | GUILFORD PHARMACEUTICALS (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020007075-A1 | Ureas of N-heterocyclic carboxylic acids and carboxylic acid isosteres | GLIAMED, INC. | 2002-01-17 | — | — | US | disclosed |
| EP-1127049-A1 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL Holdings, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1107754-A1 | UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND ISOSTERES FOR VISION AND MEMORY DISORDERS | GPI NIL Holdings, Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-1082301-A1 | UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES | GPI NIL Holdings, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000009125-A1 | UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND ISOSTERES FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999062879-A1 | UREAS AND CARBAMATES OF N-HETEROCYCLIC CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186098-A1 | Method for preventing and treating hearing loss using sensorineurotrophic compounds | GAP43, CHAT, MYOC | EPHX1 1755/4885RAB9A 3521/4885NPC1 191/4885 |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | EPHX1 494/4885RAB9A 1331/4885NPC1 3186/4885 |
| US-20020042442-A1 | Ureas and carbamates of N-Heterocyclic carboxylic acids and carboxylic acid isosteres | CPS1, OTC, NGF | EPHX1 3135/4885RAB9A 2751/4885NPC1 998/4885 |
| US-20020007075-A1 | Ureas of N-heterocyclic carboxylic acids and carboxylic acid isosteres | OTC, CPS1, ABAT | EPHX1 2694/4885RAB9A 2876/4885NPC1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.